RTP Mobile Logo

Select publications

Alimam S et al. How we diagnose and treat essential thrombocythaemia. Br J Haematol 2015;171(3):306-21. Abstract

Barbui T et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet. Leukemia 2018;32(5):1057-69. Abstract

Barbui T et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: Document summary and in-depth discussion. Blood Cancer J 2018;8(2):15. Abstract

Bose P et al. Sotatercept (ACE-011) in subjects with MPN-associated myelofibrosis and anemia. EHA 2019;Abstract S829.

Ciboddo M, Mullally A. JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program 2018;2018(1):110-7. Abstract

Curto-Garcia N et al. Molecular analysis in MAJIC PV correlation with clinical endpoints. EHA 2019;Abstract S1607.

Fenaux P et al. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood 2019;133(8):790-4. Abstract

Griesshammer M et al. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Ann Hematol 2018;97(9):1591-600. Abstract

Grinfield J et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med 2018;379(15):1416-30. Abstract

Harrison CN et al. Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study. ASCO 2019;Abstract 7057.

Harrison CN et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): A randomised, open-label, phase 3 trial. Lancet Haematol 2018;5(2):e73-e81. Abstract

Harrison CN et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): A single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 2017;4(7):e317-24. Abstract

Harrison CN et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood 2017;130(17):1889-97. Abstract

Hoffman R et al. CPI-0610, a bromodomain and extraterminal domain (bet) inhibitor, reduces pro-inflammatory cytokines, bone marrow fibrosis and the number of transfusions in myelofibrosis patients. EHA 2019;Abstract S831.

Kiladjian JJ et al. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. Ann Hematol 2018;97(4):617-27. Abstract

Mascarenhas J et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial. JAMA Oncol 2018;4(5):652-9. Abstract

Mesa RA et al. NCCN Guidelines Insights: Myeloproliferative neoplasms, version 2.2018. J Natl Compr Canc Netw 2017;15(10):1193-07. Abstract

Mesa RA et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): An international, randomised, phase 3 trial. Lancet Haematol 2017;4(5):e225-36. Abstract

Mesa RA et al. SIMPLIFY-1: A phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol 2017;35(34):3844-50. Abstract

Mesa R et al. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: A randomized, double-blind, double-dummy, symptom study (RELIEF). Br J Haematol 2017;176(1):76-85. Abstract

Mora B et al. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Med 2019;[Epub ahead of print]. Abstract

Pacilli A et al. Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. Blood Cancer J 2018;8(12):122. Abstract

Pardanani A et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. JAMA Oncol 2015;1(5):643-51. Abstract

Passamonti F et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): A randomised, open-label, phase 3b study. Lancet Oncol 2017;18(1):88-99. Abstract

Pemmaraju N et al. Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis. Proc ASCO 2019;Abstract 7058.

Pettit K et al. A phase 2a study of the LSD1 inhibitor IMG-7289 for the treatment of myelofibrosis. EHA 2019;Abstract S832.

Sokol K et al. Implications of mutation profiling in myeloid malignancies-PART 2: Myeloproliferative neoplasms and other myeloid malignancies. Oncology (Williston Park) 2018;32(5):e45-e51. Abstract

Stegelmann F et al. Ruxolitinib plus pomalidomide in myelofibrosis with anemia: Results from the MPNSG-0212 combination trial (NCT01644110). EHA 2019;Abstract S1608.

Tefferi A et al. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J 2018;8(1):2. Abstract

Tefferi A et al. Polycythemia vera treatment algorithm 2018. Blood Cancer J 2018;8(1):3. Abstract

Vannucchi A et al. Polycythemia vera and essential thrombocythemia: Algorithmic approach. Curr Opin Hematol 2018;25(2):112-9. Abstract

Vannucchi AM et al; COMFORT Investigators. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 2015;100(9):1139-45. Abstract

Vannucchi AM et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015;372(5):426-35. Abstract

Vannucchi AM et al. Ruxolitinib proves superior to best available therapy in a prospective, randomized, phase 3 study (RESPONSE) in patients with polycythemia vera resistant to or intolerant of hydroxyurea. EHA 2019;Abstract 57762.

Verstovsek S et al. A randomized, double blind phase 2 study of 3 different doses of PRM-151 in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib. EHA 2019;Abstract S828.

Verstovsek S et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol 2017;10(1):156. Abstract

Verstovsek S et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica 2016;101(7):821-9. Abstract